Immix Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMX research report →
Range $19 – $26
Price Chart
About the company
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases.
- CEO
- Ilya Rachman
- IPO
- 2021
- Employees
- 21
- HQ
- Los Angeles, CA, US
Get TickerSpark's AI analysis on IMMX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $524.43M
- P/E
- -10.95
- Fwd P/E
- 7.53
- PEG
- 0.82
- P/S
- 0.00
- P/B
- 2.69
- EV/EBITDA
- -7.45
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.44%
- ROIC
- -18.19%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-29,956,415
- Net Income
- $-29,438,613-36.2%
- EPS
- $-0.89-17.1%
- OCF Growth
- -64.0%
- FCF Growth
- -56.4%
- 52W High
- $15.10
- 52W Low
- $2.31
- 50D MA
- $11.63
- 200D MA
- $9.17
- Beta
- 0.11
- RSI (14)
- 34
- Avg Volume
- 1.67M
No earnings-call transcripts are available for IMMX yet.
- Free Float
- 79.8%
- Shares Outstanding
- 54.40M
- Float Shares
- 43.40M
of shares held by institutions
114 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jupiter Topco LLC | 9.78M | ▲ 9.78M |
| Janus Henderson Group Ltd. | 4.80M | ▲ 880.43K |
| Saturn V Capital Management LLC | 4.66M | ▲ 964.84K |
| Eventide Asset Management, LLC | 3.89M | ▲ 1.34M |
| State Street Corp | 3.00M | ▲ 2.81M |
| Blackrock, Inc. | 2.99M | ▲ 2.52M |
| Deep Track Capital, LP | 2.77M | ▲ 2.77M |
| Vanguard Capital Management LLC | 2.51M | ▲ 719.13K |
| Opaleye Management Inc. | 2.35M | ▲ 2.35M |
| Millennium Management LLC | 2.07M | ▲ 316.23K |
| Ubs Group AG | 1.94M | ▲ 1.86M |
| Marshall Wace, Llp | 1.79M | ▲ 153.36K |
Held by 117 ETFs
Biggest fund positions in IMMX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 22, 26 | Adams Helen C. | other | 6,250 |
| May 22, 26 | Adams Helen C. | other | 12,500 |
| May 22, 26 | Ng Carey | other | 6,250 |
| May 22, 26 | Ng Carey | other | 12,500 |
| May 22, 26 | Marquet Magda | other | 6,250 |
| May 22, 26 | Marquet Magda | other | 12,500 |
| May 22, 26 | Morris Gabriel S | other | 500,000 |
| May 22, 26 | CHANG NANCY T | other | 6,250 |
| May 22, 26 | CHANG NANCY T | other | 12,500 |
| May 22, 26 | Rachman Ilya M | other | 500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMMX coverage
Recent articles, reports, and earnings notes.
No research on IMMX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMMX report →Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
globenewswire.com · Oct 5
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
defenseworld.net · Oct 5
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
marketbeat.com · Oct 4
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
globenewswire.com · Sep 30
Immix Biopharma (NASDAQ:IMMX) Stock Jumps 4.1% – Should You Buy?
defenseworld.net · Sep 30
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript
seekingalpha.com · Sep 29
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
globenewswire.com · Sep 29
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
globenewswire.com · Sep 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.